Ario Pharma Information

Ario Pharma focusses on the development of drugs for the treatment of respiratory indications. Ario is evaluating the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials which will separately recruit Chronic Obstructive Pulmonary Disease (COPD) patients and chronic idiopathic cough patients. Ario is also developing TRPA1 antagonists for asthma and other inflammatory diseases. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease.

Website	http://www.ariopharma.com
Revenue	$6.2 million
Employees	3 (0 on RocketReach)
Founded	2010
Phone	+44 1223 493922
Technologies	HTML , Twitter , Google Analytics +7 more (view full list)
Industry	Biotechnology, Pharmaceutical Manufacturing, Pharmaceuticals, Biopharma, Drug Discovery, Healthcare, Drug Manufacturing & Research, Health Care, Science and Engineering, Pharmaceutical
Keywords	Respiratory Therapeutics, Pharmaceutical, Drug Development, Pharmaceutical Research, Drug Discovery, Clinical Trials, Innovative Medicines, Biopharma, Medical Research, Phase 2 Trials, New Drug Candidates, Pain Management
Competitors	Amgen, BioMarin Pharmaceutical Inc., Sarepta Therapeutics, Inc., Vertex Pharmaceuticals, Regeneron, Gilead Sciences, Novartis, AstraZeneca, Lilly India, Pfizer +41 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 2834 Companies
NAICS	NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies